Fragmento

Streptococcus agalactiae or Group B streptococci (GBS) usually colonizes gastrointestinal, respiratory, and urogenital human tracts causing diverse types of infections. Urogenital colonization of pregnant women with GBS is a critical risk factor for developing invasive neonatal disease, being the antimicrobial prophylaxis recommended during the delivery. GBS is traditionally considered to be a neonatal pathogen although recently an increasing incidence of infections among American adults, especially those patients with underlying medical conditions, has been observed. Macrolides and lincosamides are the recommended second-line agents and also a therapeutic alternative for patients with penicillin allergy. Resistance to lincosamides in S. agalactiae is commonly mediated by Erm-type methylases, which confer cross-resistance to macrolide, lincosamide and streptogramins B. Recently, LnuB (also named as LinB) and LnuC lincosamide nucleotidyl-transferase enzymes were described, in three and one S. agalactiae isolates, respectively.

Palabras clave: Streptococcus agalactiae lnuB gene lincosamide macrolide Argentina

2011-04-19   |   244 visitas   |   Evalua este artículo 0 valoraciones

Vol. 4 Núm.9. Septiembre 2010 Pags. 580-582. J Infect Developing Countries 2010; 4(9)